Active Ingredient: Isavuconazole
Isavuconazole is indicated in adults for the treatment of:
Consideration should be given to official guidance on the appropriate use of antifungal agents.
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
200 - 600 mg
From 66.667 To 200 mg 3 time(s) per day every day
600 mg
200 mg
The recommended loading dose is 200 mg of isavuconazole every 8 hours for the first 48 hours (6 administrations in total).
The recommended maintenance dose is 200 mg of isavuconazole once daily, starting 12 to 24 hours after the last loading dose.
Duration of therapy should be determined by the clinical response.
For long-term treatment beyond 6 months, the benefit-risk balance should be carefully considered.
Isavuconazole must be reconstituted and then further diluted to a concentration corresponding to approximately 0.8 mg/mL isavuconazole prior to administration by intravenous infusion over a minimum of 1 hour to reduce the risk of infusion-related reactions. The infusion must be administered via an infusion set with an in-line filter with a microporous membrane made of polyethersulfone (PES) and with a pore size of 0.2 μm to 1.2 μm. Isavuconazole must only be given as an intravenous infusion.
Oral
200 - 600 mg
From 66.667 To 200 mg 3 time(s) per day every day
600 mg
200 mg
The recommended loading dose is 200 mg of isavuconazole every 8 hours for the first 48 hours (6 administrations in total).
The recommended maintenance dose is 200 mg of isavuconazole once daily, starting 12 to 24 hours after the last loading dose.
Duration of therapy should be determined by the clinical response.
For long-term treatment beyond 6 months, the benefit-risk balance should be carefully considered.
Isavuconazole must be reconstituted and then further diluted to a concentration corresponding to approximately 0.8 mg/mL isavuconazole prior to administration by intravenous infusion over a minimum of 1 hour to reduce the risk of infusion-related reactions. The infusion must be administered via an infusion set with an in-line filter with a microporous membrane made of polyethersulfone (PES) and with a pore size of 0.2 μm to 1.2 μm. Isavuconazole must only be given as an intravenous infusion.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
